LivaNova
6
24M
6
0.17
- Areas of investment
Summary
LivaNova appeared to be the Corporate Investor, which was created in 1987. The venture was found in Europe in United Kingdom. The main office of represented Corporate Investor is situated in the London.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually.
The standard case for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, UCB Pharma, U.S. Venture Partners (USVP). In the next rounds fund is usually obtained by Venture Partners, Sofinnova Partners, Sectoral Asset Management.
The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight HighLife, MD Start, ShiraTronics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Medical, Manufacturing.
Investments analytics
Analytics
- Total investments
- 6
- Lead investments
- 0
- Rounds per year
- 0.17
- Investments by industry
- Medical Device (5)
- Health Care (5)
- Medical (2)
- Therapeutics (2)
- Specialized Finance (1) Show 6 more
- Investments by region
-
- United States (4)
- France (2)
- Peak activity year
- 2016
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cadence Neuroscience | 28 Feb 2023 | Health Care, Neuroscience, Therapeutics | Early Stage Venture | 26M | United States, Washington |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.